The modulation of mRNA turnover is gaining recognition as a mechanism by which Staphylococcus aureus regulates gene expression, but the factors that orchestrate alterations in transcript degradation are poorly understood. In that regard, we previously found that 138 mRNA species, including transcripts coding for the virulence factors protein A (spa) and collagen-binding protein (cna), are stabilized in a sarA-dependent manner during exponential phase growth, suggesting that SarA directly or indirectly affects the RNA turnover properties of these transcripts. Herein, we expanded our characterization of the effects of sarA on mRNA turnover during late-exponential and stationary phases of growth. Results revealed that the locus affects the RNA degradation properties of cells during both growth phases. Further, using gel mobility shift assays and RIP-Chip, it was found that SarA protein is capable of binding mRNA species that it stabilizes both in vitro and within bacterial cells. Taken together, these results suggest that SarA post-transcriptionally regulates S. aureus gene expression in a manner that involves binding to and consequently altering the mRNA turnover properties of target transcripts.
INTRODUCTION
Staphylococcus aureus is a human pathogen that causes nosocomial and community-associated infections that result in high rates of morbidity and mortality (Klevens et al., 2007; Deleo et al., 2010) . The organism largely owes its ability to cause infection to the production of an array of virulence factors which, in the laboratory setting, are coordinately regulated in a cell densitydependent manner. Cell surface-associated factors are predominantly expressed during exponential phase growth whereas extracellular factors are predominantly produced during stationary phase growth (Novick, 2003; Bronner et al., 2004) . The organism's virulence factors are also coordinately regulated in response to endogenous and exogenous cues, including cellular stresses and sub-inhibitory concentrations of antibiotics. A plethora of two component regulatory systems (TCRS) and nucleic acid-binding proteins have been hypothesized to modulate S. aureus virulence factor expression.
Of the 17 TCRS identified in S. aureus to date, the bestcharacterized is the accessory gene regulator (agr) locus. The agr locus encodes a quorum-sensing TCRS, AgrAC, whose regulatory effects are generally thought to be mediated by a regulatory RNA molecule, RNAIII. Within laboratory culture conditions, RNAIII expression peaks during the transition to stationary phase growth (Novick, 2003) . RNAIII has been shown to modulate virulence factor expression by directly binding to target mRNA species, thereby affecting their stability and translation properties (Morfeldt et al., 1995; Huntzinger et al., 2005; Geisinger et al., 2006; Boisset et al., 2007) . For instance, RNAIII binding to the cell surface factor protein A (spa) transcript creates a substrate for ribonuclease III digestion, which, in-turn, accelerates spa mRNA digestion and consequently limits Spa production (Huntzinger et al., 2005) . Conversely, the binding of RNAIII to the extracellular virulence factor α-hemolysin (hla) transcript liberates the mRNA's ShineDalgarno sequence and increases Hla production (Morfeldt et al., 1995) . Similar mechanisms of RNAIII regulation have been documented for the virulence factor coa (Chevalier et al., 2010) and the regulatory locus repressor of toxins (rot ; Boisset et al., 2007) .
In addition to TCRS, S. aureus produces a family of DNAbinding proteins that regulate virulence factor expression. The best-characterized to date is the staphylococcal accessory regulator nucleic acid-binding protein, SarA. The sarA locus consists of a 1.2 kb DNA region that produces three overlapping transcriptional units (sarB, sarC, and sarA), each of which terminates at the same site and encodes for the SarA protein (Chien and Cheung, 1998) . Unlike RNAIII, SarA is constitutively produced throughout S. aureus growth phases, however the expression of the individual sar Frontiers in Cellular and Infection Microbiology www.frontiersin.org transcripts occurs in a growth phase-dependent manner; sarA and sarB are primarily transcribed during exponential phase growth whereas sarC is predominantly expressed during stationary phase growth (Manna et al., 1998; Blevins et al., 1999) . SarA has been characterized as a pleiotropic transcriptional regulator of virulence factors that can bind to the promoter regions of a subset of genes that it regulates, such as hla (α-hemolysin) and spa (protein A; Chien and Cheung, 1998; Chien et al., 1999) . Nonetheless, several observations have suggested that SarA's regulatory effects might be more complex than initially appreciated. Arvidson and colleagues have reported that, in addition to affecting spa transcript synthesis, SarA may also indirectly regulate Spa production (Tegmark et al., 2000) . Further, no clear SarA consensus binding site has been defined; Cheung and colleagues found that SarA binds a 26 base pair (bp) region termed the SarA box, whereas Sterba et al. (2003) have defined the SarA box to be a 7 bp sequence, which is present more than 1000 times within the S. aureus genome, indicating that the protein may have the capability of binding the chromosome more frequently than one might expect for a bona fide transcription factor (Chien et al., 1999) . In that regard, others have suggested that SarA is a histone-like protein whose regulatory effects are a function of altering DNA topology and, consequently, promoter accessibility (Schumacher et al., 2001 ).
In Escherichia coli, histone-like proteins can post-transcriptionally regulate gene expression by binding directly to mRNA molecules and influencing the transcript's stability and translation (Balandina et al., 2001; Brescia et al., 2004) . Accordingly, based on the possibility that SarA may behave as a histone-like protein, we hypothesized that the protein's regulatory effects may, in part, be due to its ability to bind and subsequently modulate the mRNA turnover properties of target transcripts. As a first step toward testing that prediction, we found that 138 mRNA species that are produced during S. aureus exponential phase growth, including the known SarA-regulated genes spa and cna, are also stabilized in a sarA-dependent manner . More specifically, these mRNA transcripts are stabilized in a sarA + background as compared to isogenic sarA − cells, raising the possibility that SarA protein may bind these transcripts in a manner that affects their stability and, consequently, expression. In the current body of work we extended our evaluation of this phenomenon by investigating whether the mRNA turnover properties of late-exponential and/or stationary phase transcripts are also modulated in a sarAdependent manner. Results revealed that this is indeed the case; the sarA locus affects the mRNA turnover properties of transcripts produced during both phases of growth. Further, using ribonucleoprotein immunoprecipitation (RIP-Chip) assays, we found that SarA binds these transcripts within S. aureus cells. Results were verified via gel-shift mobility assays. Taken together, these results indicate that SarA is capable of binding cellular mRNA species and that the protein's regulatory effects could be attributable to its ability to directly modulate the mRNA turnover properties of target mRNA species.
MATERIALS AND METHODS

GROWTH CONDITIONS
Bacterial strains and plasmids used in this study are listed in Table 1 . Overnight S. aureus cultures were diluted 1:100 into Aliquots of cells were removed at 0, 2.5, 5, 15, and 30 min posttranscriptional arrest, mixed with an equi-volume of ice-cold acetone:ethanol (1:1) and RNA was isolated, as previously described Roberts et al., 2006; Olson et al., 2011) .
GENECHIP ® MICROARRAYS
All microarray studies were performed as previously described (Anderson et al., , 2010 Roberts et al., 2006; Olson et al., 2011) . Briefly, 10 μg of each bacterial RNA sample was labeled and hybridized to a S. aureus GeneChip®, following the manufacturer's recommendations for antisense prokaryotic arrays (Affymetrix; Santa Clara, CA). Average GeneChip®signal intensities for biological replicates (n ≥ 2) for each strain and time point were obtained from values normalized to exogenous transcripts. The half-life of each RNA transcript was determined using a "twofold" algorithm (Selinger et al., 2003) and was measured as the time point at which a given RNA signal intensity decreased two-fold as compared to that transcript at 0 min post-transcriptional arrest using GeneSpring 7.2 software (Agilent Technologies; Redwood City, CA).
IN VITRO TRANSCRIPTION
DNA templates consisting of the full-length spa transcriptional unit or derivatives containing 3 or 5 deletions were created by PCR amplification using UAMS-1 chromosomal DNA as a template and oligonucleotides listed in indicated RNA species. Template DNA was degraded with four units of TurboDNase I for 15 min at 37 o C, and in vitro transcribed RNA was recovered by lithium chloride precipitation and resuspended in nuclease-free water. RNA concentration of the synthesized product was determined spectrophotometrically (OD 260 nm 1.0 = 40 μg ml −1 ) and the integrity of the transcript was evaluated on a 1.2% agarose-0.66 M formaldehyde denaturing gel.
ELECTROPHORETIC MOBILITY SHIFT ASSAY
In vitro transcribed spa mRNA or a PCR product containing the endogenous hla promoter were 3 end-labeled with digoxigenin-ddUTP (DIG; Roche Applied Science; Indianapolis IN) following the manufacturer's recommendations. One picomole DIG-mRNA or -DNA was mixed with 0, 7.3, 36.6, 73.3, or 366 .5 pmol purified SarA protein then, incubated for 15 min at 37 o C in gel-shift buffer (20 mM HEPES-KOH, pH 8.0, 8 mM MgCl 2 , 100 mM NaCl), cooled on ice and the entire sample volume was electrophoresed in 1.2% agarose-0.66 M formaldehyde denaturing gels. Next, RNA-protein or DNA-protein complexes were transferred via capillary action to nylon membranes overnight in 20× SSC buffer (3 M NaCl, 300 mM sodium citrate, pH 7.0). Nucleic acid was then cross-linked to the membrane by UV irradiation in a Stratalinker®UV crosslinker (Stratagene; La Jolla, CA) twice at 1200 (×100) microjoules. Membranes were probed for presence of the DIG-labeled RNA or DNA using anti-DIG Fab fragments conjugated to alkaline phosphatase (1:10,000; Roche Applied Science) and visualized chemiluminescently with CSPD reagent (Roche Applied Science). For all binding assays, bovine serum albumin (BSA) was used as a negative control for non-specific RNA-protein and DNA-protein interactions.
c-Myc-SarA CONSTRUCTION
A c-Myc epitope was translationally fused to the C-terminus of the SarA open reading frame. To do so, 615 bp of the S. aureus strain UAMS-1 sarA gene and its corresponding P1 promoter region were amplified by PCR using primers c-Myc-SarA F and c-Myc-SarA R (Table 2) ; the latter included a c-Myc epitope and 3 flanking restriction enzyme site. The resultant PCR product was gel-purified and digested with restriction enzymes SalI and BamHI and subcloned into pBK123 (Charpentier et al., 2004) to generate the plasmid pKLA40. Plasmid pKLA40 was then electroporated into the restriction-negative strain of S. aureus, RN4220 (de Azavedo et al., 1985) and transfected into UAMS-929 (ΔsarA) via ϕ11-mediated phage to generate strain KLA43 and the plasmid was sequenced to confirm the integrity of the insert. c-MycSarA functionality was confirmed by examining the ability of the epitope-tagged protein to complement the exoprotein profile of UAMS-929(ΔsarA) cells. Briefly, supernates from stationary phase cultures of S. aureus UAMS-1, UAMS-929(ΔsarA), and KLA43 (ΔsarA; c-Myc-SarA) were collected, filtered through a 0.22 μm nylon membrane, and compared by electrophoresis in sodium dodecyl sulfate-polyacrylamide gels and silver staining (Bio-Rad Life Science, Hercules, CA).
WESTERN BLOTTING
Cultures were grown to the indicated growth phase and cells were mechanically disrupted in TE buffer in BIO101 lysing matrix B tubes using a FastPrep120 shaker (MP Biomedicals; Solon OH). Cell debris was removed by centrifugation at 4 o C for 15 min and the protein concentration of supernatants were quantified by Bradford protein assays. For confirmation of c-Myc-SarA expression, 1 μg of protein was electrophoresed in a 15% sodium dodecyl Confirmation of successful RIP was confirmed by loading 10 μl of cell lysate, cell supernate, wash, or elution fractions and subjected to SDS-PAGE and western blotting, as described above.
RIBONUCLEOPROTEIN IMMUNOPRECIPITATION (RIP-Chip)
Ribonucleoprotein immunoprecipitation was performed using a c-Myc Tag/Co-IP Kit (Pierce Biotechnology; Rockford, IL). To do so, S. aureus strains UAMS-929 (ΔsarA; negative control) and KLA43 (ΔsarA/pKLA40::c-Myc-SarA) were grown to midexponential phase and RNA-binding proteins were cross-linked to RNA by incubating the cells for 30 min with 1% formaldehyde at room temperature. Cross-linking was quenched by adding 125 mM glycine for 5 min at room temperature. Cells were centrifuged at 3000 RPM for 10 min at 4 o C and cell pellets were washed twice in 1 ml ice-cold TBS, resuspended in 350 μl of lysis buffer (10 mM Tris pH 8.0, 10 mM EDTA, 50 mM NaCl, and 1 mM PMSF) and were lysed by the addition 100 μg ml −1 lysostaphin (Ambi; Lawrence, NY) at 37 o C for 30 min. Next, an equal volume of 2× immunoprecipitation (IP) buffer (100 mM Tris pH 8.0, 10 mM EDTA, 300 mM NaCl, 2% Triton X-100, 1 mM PMSF) was added and suspensions were incubated for an additional 10 min at 37 o C. Nucleic acids were fragmented with a Sonic Dismembrator (Fisher) on ice twice for 15 s using an output setting of one with 15 s rests on ice between each pulse and cell debris was subsequently removed by centrifugation for 10 min at 4 o C. Next, 800 μl of the supernatant was mixed with 10 μl of anti-c-Myc agarose (Pierce Biotechnology; Rockford IL) and then added to IP spin columns (Pierce Biotechnology) and incubated overnight at 4 o C to collect c-Myc-SarA/RNA and DNA complexes. Columns were washed five times with 1× IP buffer and c-Myc-SarA complexes were eluted in 50 μl of elution buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) by first incubating at 65 o C for 10 in followed by centrifugation at 4 o C to collect eluate. Cross-linking was reversed by incubating eluate for 2 h at 42 o C and then 6 h at 65 o C in 0.5× elution buffer containing 0.8 mg ml −1 pronase. For chromatin immunoprecipitation (ChIP-chip) experiments used to detect known SarA-DNA interactions, liberated DNA was purified using a PCR Clean-Up Kit (Qiagen) per manufacturer's recommendations and hybridized to a GeneChip®and processed as described above. For RIP-chIP experiments, liberated nucleic acid was treated with 17 U of RNase-Free DNase I (Qiagen) and RNA was purified using a Clean and Concentrator Kit (Zymo Research; Orange, CA) according to the manufacturer's recommendations. All assays were performed in triplicate for each strain and purification of the c-Myc-SarA protein was confirmed via Western blotting. Following IP, bacterial RNA was amplified and reversetranscribed using a MessageAmp II-Bacteria Prokaryotic RNA Amplification Kit (Ambion). 1.5 μg of the amplified cDNA was then hybridized to a GeneChip®and processed as described above. The fold change in average signal intensity of KLA43 replicates as compared to the average signal intensity of UAMS-929 (negative control) replicates was calculated for each GeneChip®qualifier. SarA was considered to bind DNA or transcripts that exhibited a signal intensity that was ≥ two-fold in KLA43 samples and greater than two standard deviations from the average signal intensity (background), as compared to UAMS-929 cells.
QUANTITATIVE REVERSE-TRANSCRIPTION PCR
For standard qRT-PCR reactions, 25 ng of total bacterial RNA were reverse-transcribed, amplified, and measured using a LightCycler®RNA Master SYBR Green I kit per the manufacturer's recommendations (Roche Applied Science). As an internal control by which to standardize RNA loading, 0.5 pg of RNA was used to quantitate the amount of 16S rRNA in each sample. Transcript concentrations were calculated using LightCycler®software and LightCycler®Control Cytokine RNA titration kit as a standard for determining the copies of each transcript present per reaction. Final concentration values are listed as normalized to 16S rRNA abundance. Transcript half-lives were calculated as the time point at which RNA titers exhibited a ≥ two-fold decrease in signal intensity.
RESULTS
It is well recognized that SarA is a pleiotropic regulator of S. aureus virulence factors, yet the mechanism(s) by which the protein affects gene expression is incompletely understood. Several studies have shown that the molecule affects the transcript synthesis of target genes, however the lack of a consensus SarA-binding sequence and evidence of indirect control of gene expression have implicated SarA in post-transcriptional control of gene expression. Accordingly, it has also been hypothesized that SarA regulates S. aureus gene expression via modulating the mRNA turnover properties of target transcripts. In support of this hypothesis, we have previously shown that 138 mRNA species, including the virulence factor transcripts protein A (spa) and collagen-binding protein (cna) are stabilized in a sarA-dependent manner . Our current efforts are designed to expand upon these initial studies and further define the role for sarA in modulating mRNA turnover.
sarA STABILIZES SUBSETS OF mRNA SPECIES IN A GROWTH PHASE-DEPENDENT MANNER
Herein, we set out to establish whether the degradation properties of mRNA species that are expressed during late-exponential and/or stationary phase growth are affected by a product of the sarA locus. To do so, S. aureus UAMS-1 (wild type) and UAMS-929 (UAMS-1ΔsarA) were grown to late-exponential or stationary phase growth and transcription was halted by the addition of rifampicin. Total bacterial RNA was then purified from aliquots of cells at 0, 2.5, 5, 15, and 30 min post-transcriptional arrest and the mRNA titers of expressed transcripts were then measured using Affymetrix GeneChips®. A comparsion of each transcript's titer at 0 min post-transcriptional arrest to that of each subsequent time point allowed the half-lives of each mRNA to be measured, as
Frontiers in Cellular and Infection Microbiology www.frontiersin.org previously described (Anderson et al., , 2010 Roberts et al., 2006; Olson et al., 2011) . As shown in Figure 1 , in general terms, the global RNA turnover properties of UAMS-1 and UAMS-1ΔsarA cells exhibited a similar trend that is consistent with our previous observations; bulk mRNA turnover occurs more rapidly in exponential phase as compared to stationary phase cells (Olson et al., 2011) . Despite these similarities, a more detailed analysis of RNA degradation properties of individual mRNA species within each strain background indicated that sarA influences the stability of many transcripts. More specifically, 93.2 and 48.4% of transcripts exhibited halflives of <2.5 min during late-exponential and stationary phase growth, respectively, in the wild type strain (Table 3) . Conversely, 76.9 and 32.5% of transcripts were degraded within 2.5 min in late-exponential and stationary phase ΔsarA cells, suggesting that sarA affects the stability of a subset of transcripts. Within this subset, 68 (3.2%; Supplemental Results also indicated that the mRNA turnover properties of many virulence factors are influenced by sarA, but that these effects predominantly occur during stationary phase growth. More specifically, during late-exponential phase growth the transcripts coding for three virulence-associated genes were stabilized in a sarA-dependent manner ( Table 4) . Among these were two metabolic enzymes, enolase (eno; Carneiro et al., 2004) and carbamate kinase (arc; Beenken et al., 2004; Diep et al., 2006; Diep and Otto, 2008) , both of which exhibited half-lives of 30 min in wild type cells but only 15 min in ΔsarA cells. Likewise, the ATP-dependent protease clpP (Frees et al., 2003 (Frees et al., , 2005 Michel et al., 2006) , exhibited a half-life of 15 min in wild type cells, but was reduced to five min in the sarA-mutant. During stationary phase growth at least 13 virulence factor transcripts were stabilized in a sarA-dependent manner ( Table 4) . Included among these were: spa (protein A), hla (α-hemolysin), hlb (β-hemolysin), and hlgCB (γ-hemolysin), as well as members of the capsule operon (cap) and the cell surfaceassociated factors fnbA (encoding fibronectin binding protein A) and cna (encoding a collagen-binding protein). Quantitative RT-PCR-based determination of select virulence factor half-lives within stationary phase wild type and ΔsarA cells verified the microarray-based RNA turnover measures ( Table 5 ). In addition to virulence factors, three virulence factor regulatory molecules, agrA, sarS, and saeS, were stabilized in a sarA-dependent manner. (Cassat et al., 2006) .
SarA BINDS mRNA IN VITRO
The results presented here are consistent with previous observations suggesting that the sarA locus affects S. aureus mRNA turnover properties with exponential phase cells . The two most likely scenarios that could account for these observations are that a product of the sarA locus may directly interact with and subsequently affect the mRNA degradation properties of target transcripts or that SarA indirectly modulates the organism's mRNA turnover properties by regulating other factors that affect S. aureus RNA decay. As a preliminary means of distinguishing between these two possibilities we set out to determine whether SarA is an RNA-binding protein. To do so, electrophoretic mobility shift assays (EMSAs) were performed to investigate whether purified SarA protein directly binds to spa transcripts, an mRNA species that is stabilized in a sarA-dependent manner . Accordingly, various amounts (0, 7.3, 36.6, 73.3, or 366.5 pmol) of purified SarA protein were incubated with DIG-labeled, in vitro transcribed spa mRNA, during experimental conditions that have previously been used to establish that SarA binds to the promoter region of the α-hemolysin (hla) gene (Chien et al., 1999) . As shown in Figure 2A , during these assay conditions SarA protein did indeed bind to the hla promoter region, confirming that the experimental conditions are appropriate to measure SarA-nucleic acid interactions and further validating the work of Chien et al. (1999) . Similarly, the EMSA revealed that SarA elicited a dose-dependent shift in mobility of labeled spa mRNA, suggesting that SarA may be capable of binding RNA molecules ( Figure 2B ). Gel-shift assays were also performed with BSA and a S. aureus stable RNA, SSR42 (Olson et al., 2011) , to determine if non-staphylococcal proteins would bind to the in vitro transcribed mRNA and whether SarA alters the mobility of any RNA species, respectively. Results of those studies indicated that BSA did not affect the mobility of spa transcript and, likewise, that SarA did not affect the migration of in vitro transcribed SSR42 ( Figure 2C) . RNA-binding proteins have been shown to bind to specific regions of target mRNAs (Folichon et al., 2003; Wang et al., 2005) ; to test this possibility with SarA, we used EMSAs to measure the protein's ability to bind different regions of in vitro transcribed spa mRNA: a region lacking bases 1-320 of the 5 end (L-250) and a fragment of spa containing only bases 1-450 (L 1-450; Figure 2D ). As seen in Figure 2E , SarA affected the mobility of both RNA species. Further, a higher molecular weight product was observed when SarA was incubated with spa RNA fragments containing an intact 5 region (450 nt) in comparison to fragments lacking bases 1-250 of the transcript (1,100 nt), suggesting that the 5 end of the spa transcript may harbor a greater number of SarA-binding sites than the 3 terminus. Taken together, these results suggest that SarA may be capable of binding both DNA and RNA molecules.
SarA BINDS mRNA IN VIVO
Based on the observations that many exponential phase transcripts, including spa, are stabilized in a sarA-dependent manner and that SarA protein is capable of altering the mobility of spa transcripts in vitro, we set out to determine whether the protein is capable of binding mRNA species within bacterial cells using ribonucleoprotein immunoprecipitation-microarray (RIP-Chip) assays. To do so, we needed to create a means of capturing cellular SarA protein. Accordingly, the SarA open reading frame was translationally fused to a C-terminal c-Myc epitope. This construct was placed under control of the sarA endogenous P1 promoter and was inserted into plasmid pCN51 to generate pKLA40. This plasmid was transfected into UAMS-929 (ΔsarA) cells to generate strain KLA43 and the expression properties of C-Myc-SarA protein were evaluated. It should be noted that the c-Myc epitope has been shown to exhibit little or no non-specific nucleic acid binding in previous assays (Pannone et al., 1998) . As expected, RT-PCR and Western blotting using anti-c-Myc antibodies established that the chimeric protein was expressed within KLA43 cells ( Figures 3A,B) during mid-and late-exponential as well as stationary phase growth. We also confirmed that c-Myc-SarA was capable of complementing SarA's regulatory effects within ΔsarA cells. Specifically, sarA-mutant cells have been reported as exhibiting altered exprotein profiles due to alterations in the control of gene expression (Tegmark et al., 2000) . Thus, we evaluated the ability of the c-Myc-SarA construct to complement the exoprotein profile of supernates from stationary phase cultures of S. aureus strain UAMS-929 (ΔsarA). As shown in Figure 3C , the c-Myc-SarA construct at least partially complemented the exoprotein profile of ΔsarA cells, indicating that presence of the epitope did not significantly affect SarA's regulatory capacity and, consequently, the chimeric protein was appropriate for studying SarA's cellular role as an RNA-binding protein.
Having confirmed that the chimeric protein was expressed and functional within ΔsarA cells, RIP-chIP assays were performed using anti-c-Myc immunoglobulin immobilized on agarose beads to capture cellular c-Myc-SarA-bound transcripts. To do so, KLA43 (ΔsarA c-Myc-SarA) was grown to mid-exponential phase and the proteins were cross-linked to nucleic acids with 1% formaldehyde to stabilize any interactions between c-Myc-SarA and RNA molecules. Cells were lysed and c-Myc-SarA protein was then immunoprecipitated with the anti-c-Myc agarose beads, co-precipitating any bound RNA species. Western blotting of the cell lysates and RIP intermediates indicated the presence of the epitope-labeled SarA through sequential steps of the IP process ( Figure 3D) . After reversal of the RNA cross-linking, the RNA was purified, treated with DNase, amplified, labeled, and applied to a S. aureus GeneChip®. All RIP-Chip assays were performed in triplicate for both KLA43 (ΔsarA c-Myc-SarA) and ΔsarA cells (negative control). A transcript was considered to be bound by c-Myc-SarA if its average signal intensity value was ≥ two-fold in KLA43 cells as compared to the negative control. It should be noted that as a prerequisite to performing RIP-Chip assays we exploited SarA's known ability to bind the hla promoter region and the fact that the microarray used in this study contains intergenic regions representing gene promoters to determine whether our experimental approach was appropriate for studying cellular SarA-nucleic acid interactions. Results from ChIP-chip experiments revealed that the signal intensity of the intergenic region representing the hla promoter region exhibited a signal increase beyond the established threshold (≥ two-fold) in samples from KLA43 cells as compared to UAMS-929 cells, indicating that the experimental approach was capable of detecting known in vitro protein-nucleic acid reactions in vivo (data not shown). RIP-Chip assays results indicated that cellular c-Myc-SarA is capable of binding to a total of 115 RNA species, including eight virulence factor transcripts (Supplemental Table S5 in Supplementary Material). Of the virulence factor transcripts bound by SarA (Table 6) , spa and arcB were also stabilized in a sarA-dependent manner in at least one of the growth phases studied here (latelog and stationary phase) or by our laboratory previously (midexponential phase; Roberts et al., 2006 and that SarA protein is capable of binding the transcript during in vitro conditions and within bacterial cells. When taken together, these results suggest that SarA may post-transcriptionally regulate gene expression by binding to and modulating the RNA degradation properties of target transcripts.
DISCUSSION
Staphylococci produce an array of TCRS and DNA-binding proteins that are thought to modulate virulence factor transcript synthesis, providing the pathogen with a means for sensing and responding to environmental stresses including exposure to subinhibitory concentrations of antibiotics (Novick, 2003) . By definition, transcript titers are a function of both transcript synthesis and degradation, and mounting evidence strongly suggests that orchestrated changes in mRNA degradation mediate the organism's ability to regulate gene expression. Indeed, the global mRNA degradation properties of S. aureus are significantly altered in response to growth phase, stringent response-inducing conditions, and pH and temperature stress (Anderson et al., , 2010 Olson et al., 2011) . With respect to growth phase, RNA turnover is rapid in exponential phase cells whereas a global stabilization of RNA transcripts occurs during stationary phase growth; ∼90% of transcripts decay within 5 min during mid-exponential growth while only ∼50% of all transcripts decay within 5 min during stationary phase growth (Olson et al., 2011) . Presently, the factors that mediate this transition between RNA degradation profiles are poorly characterized. Because all transcripts do not degrade at the same rate, it has been hypothesized that transacting factors, such as RNA-binding proteins or regulatory RNAs, may affect mRNA stability. Indeed, the mRNA turnover properties of nearly 150 exponential phase mRNA species, including the cell surface-associated virulence factors spa and cna, have been reported to be stabilized in a sarA-dependent manner . However, those studies were limited in scope, in that the effects of sarA on RNA stability were only studied within mid-exponential phase cells. In the present work, we evaluated the effects of sarA on late-exponential and stationary phase RNA turnover. A comparison of mRNA turnover within wild type and ΔsarA cells indicated that global RNA decay is similar between the two strains; mRNA is rapidly degraded in late-exponential phase cells but transcripts become more stable during stationary phase growth. Despite these similarities, transcript turnover within each growth phase was slightly decreased in ΔsarA cells indicating that a product of the sarA locus affects the stability of a subset of mRNA species. Indeed, sarA was found to both stabilize and destabilize transcripts in each growth phase; 3.4 and 16.5% of transcripts were stabilized, whereas 16.4 and 23.5% of transcripts were destabilized in a sarA-dependent manner within late-exponential and stationary phase cells, respectively. Among the stabilized transcripts were those encoding for translation machinery, suggesting that sarA may modulate protein production indirectly by posttranscriptionally altering expression of the translation apparatus. Perhaps more relevant to S. aureus pathogenesis, 19 virulenceassociated factors were stabilized in a sarA-dependent manner, including cell surface components, secreted enzymes and toxins, transcriptional regulators, and antibiotic resistance determinants.
Interestingly, a subset of these virulence factors, including spa, hla, sak, and sspB have been previously shown to be regulated by sarA at the transcriptional level (Cassat et al., 2006) . These results suggest that the effects of sarA on gene regulation in S. aureus may be more complex than previously thought, and that a product of the locus may post-transcriptionally regulate gene expression.
The sarA locus is capable of producing three distinct transcripts, each of which encode for and result in the production of SarA protein. Thus, any potential post-transcriptional regulation could occur via the SarA protein or via one of the transcribed mRNAs as has been described with other regulatory RNAs in S. aureus (reviewed in Felden et al., 2011) . The mRNA turnover properties of ΔsarA cells harboring plasmid-borne copies each of these three transcriptional units demonstrated that their RNA degradation properties mimicked one-another, suggesting that the SarA protein (as opposed to a particular sarA transcriptional unit) accounts for the sarA-dependent modulation of mRNA turnover (data not shown). Thus, we predicted that SarA directly or indirectly affects the RNA degradation properties of target transcripts. Accordingly, gel-shift assays were performed to determine whether SarA protein directly binds to spa mRNA in vitro, a transcript that is stabilized in a sarA-dependent manner. EMSA results revealed that SarA alters the mobility of spa mRNA in a concentrationdependent manner, suggesting that the protein is capable of binding the transcript in a cooperative manner. We hypothesize that this may reflect two potential dynamic properties of the interaction: (1) SarA oligomerizes when binding RNA or (2) the spa transcript contains multiple SarA-binding sites such that in the presence of excess SarA the number of sites bound by the protein are increased. Further, gel-shift assays indicated that SarA exhibits a greater propensity to cause a higher molecular shift of the 5 -end of spa mRNA, suggesting that either the 5 end of the message harbors a higher incidence of SarA-binding sites or that the secondary structure of the transcript's 5 end reduces the amount of steric hindrance. Regardless, we conclude from the results of these assays suggest that the SarA-mRNA interaction is not likely to be equal across the entire length of the spa transcript.
In order to characterize the physiological relevance of SarA's potential RNA-binding properties, we performed in vivo RIP-chIP assays to identify the transcripts with which the protein could interact within bacterial cells. To do so, c-Myc epitope-tagged SarA was expressed in ΔsarA cells and immunoprecipitated; c-MycSarA-bound RNA molecules were subsequently identified using GeneChips®. In total, SarA was found to interact with 115 mRNA species, including eight virulence factors. Specifically, two of the virulence factor transcripts that bound to SarA in vivo were also found to be stabilized in a sarA-dependent manner, including the spa transcript, an mRNA species that SarA appears to bind in vitro. Taken together, these data suggest that SarA may alter the stability of target transcripts by directly binding to these mRNA species, which could, in-turn, limit the RNA molecule's accessibility to degradation machinery. Additionally, SarA also interacted with three transcripts that are destabilized in a sarA-dependent manner, suggesting that the protein:mRNA interaction may catalyze a conformational change in the substrate RNA molecule that makes it more susceptible to ribonuclease attack. In addition to ORFs, SarA also bound five transcripts that mapped to intergenic regions and may represent non-coding RNA molecules. Collectively, the data presented here indicate that SarA interacts with RNA in a biologically relevant setting and that these interactions correlate with alterations in the degradation properties of a subset of those mRNA species. Thus, we hypothesize that SarA post-transcriptionally regulates gene expression via binding to and consequently modulating the mRNA turnover properties of target transcripts. There is precedence for this prediction in other organisms. For instance, in Escherichia coli, CsrA is an RNA-binding protein that modulates virulence factor expression, in part, by both stabilizing and destabilizing target transcripts. For instance, CsrA associates with the 5 untranslated region of the pgaA transcript, which blocks translation of the molecule and subsequently destabilizes the transcript (Wang et al., 2005) . CsrA has also been shown to bind the flhDC transcript, stabilizing the molecule and ultimately contributes to bacterial motility (Wei et al., 2001) . Given the similarities of CsrA and other RNA-binding proteins to SarA, scenarios by which SarA can post-transcriptionally modulate gene expression emerge. In the case of spa, whose transcript is stabilized but protein production is repressed by SarA, binding of the RNA may simultaneously inhibit activity of the translational machinery and ribonucleases (RNases). This mechanism would presumably provide the cell with a mechanism to repress protein A production, in a manner that when inactivated would allow for efficient induction of Spa production without having to expend energy to synthesize new transcripts. Our finding that SarA seems to preferentially interact with the 5 terminus of the spa transcripts supports this prediction, as the 5 end of mRNA not only serves as a potential entry point for the RNA degradation machinery, it is also the loading site for the translation apparatus. Similarly, the binding of SarA to transcripts which are normally stabilized and for which protein levels are increased, SarA could function by inhibiting degradation of the transcript by RNases, thus facilitating increased production of protein. As what occurs with CsrA, SarA also destabilizes transcripts that it binds in vivo, suggesting that this interaction could expose transcripts to cleavage by RNases. It was also observed that virulence factor transcripts that were stabilized in a sarA-dependent manner were not bound by SarA in vivo (Supplemental Table S5 in Supplementary Material). Thus, one can assume that the modulation of RNA stability of these transcripts is indirect; presumably, SarA regulates another factor, such as a regulatory RNA or other RNA-binding protein, which ultimately mediates the alteration in stability. While the biological significance of sarA-dependent control of mRNA stability is not yet fully understood, these results indicate that SarA is an RNA-binding protein with the potential to post-transcriptionally regulate the mRNA and consequently protein production of target transcripts. These results may have expanded significance in that SarA represents a prototypical regulatory molecule with a multitude of homologs within S. aureus and other bacterial pathogens.
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